Recently, it is found that the drug advertisements about hepatitis B treatment all over the world have turned to the TV health column and newspaper news column, with huge length, illustrated and illustrated, and more than one “scientific unique” medicinal mechanism to elaborate its excellent efficacy, which seriously misleads the majority of patients and friends. Experts suggest that 1. for those who have hepatitis B infection with normal liver function, no treatment is needed, and they should be followed up and observed, and treatment should be considered when aminotransferase (ALT) is elevated. 2. patients whose aminotransferase is more than 2 times of the upper limit of the normal value and continues to be elevated (with at least 1 month interval between the tests) should be considered for treatment. 3. patients with positive HBV DNA and aminotransferase more than 2 times of the upper limit of the normal reference value should be considered for treatment. 4. patients with transaminase more than 2 times of the upper limit of the normal reference value should be considered for treatment. Treatment should be considered for patients with positive HBV DNA whose transaminases are more than two times the upper limit of normal reference values. 4. Patients with increasing transaminases (ALT markers) (from normal or lower levels) or ALT greater than five times the upper limit of normal reference values may be experiencing exacerbation of the disease, fulminant hepatitis, or hepatic decompensation. Therefore, these patients should be closely monitored and treated in a timely manner to prevent hepatic decompensation. Since exacerbation may be followed by spontaneous seroconversion of HBeAg and subsequent remission, treatment may be delayed and followed by 3 months of observation if there are no signs of hepatic decompensation (which can be suggested by medical history, liver histology, serum bilirubin, albumin levels and platelet count).